A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Lassen Therapeutics 1 PTY LTD75 enrolled

Overview

LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED. This study is a four-part trial consisting of Parts A, B, C and D. The primary objective of this study is to evaluate the safety and tolerability of LASN01, and the secondary objective is to evaluate the preliminary efficacy, immunogenicity, and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or Thyroid Eye disease (TED). Please note that both the Phase 1 (single and multiple ascending dose, SAD/MAD) portion in healthy volunteers and the Phase 2a portion in patients are completed.

This randomized, placebo-controlled clinical trial (LASN01-CL-1101) consists of 4 parts, each part containing adaptive design elements that can be modified. In Phase 1, Part A comprised of a single-dose administration in healthy participants in 5 dose cohorts and Part B comprised of a multiple-dose administration in healthy participants in 2 dose cohorts. Parts A\&B have been completed. In the Phase 2a portion, Part C comprised of a multiple-dose administration in a single cohort of patients with IPF and PF-ILD, and Part D comprised of a multiple-dose design in a single cohort of patients with TED. In each part of the study, participants were randomized to receive IV doses of LASN01 or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

I. Participant Inclusion Criteria- Parts A, B, C, and D 1. Female participants must be nonpregnant, nonlactating, and either postmenopausal for ≥12 months, surgically sterile for ≥6 months, or agree to use 2 effective methods of contraception or a highly effective method of contraception. Males must be surgically sterile for ≥6 months or agree to highly effective methods of contraception. 2. Able to comprehend and willing to sign an ICF and understand and comply with the requirements of the study. Part A and Part B only 3. Males or females, 18 through 60 years of age, inclusive 4. Body weight ≥110 pounds (≥50 kg); body mass index (BMI) within the range of 18 through 32.0 kg/m2 5. In good health as determined by the Investigator Part C only 6. Male and female patients \>40 years of age (IPF patients) or ≥21 years of age (PF-ILD patients) IPF-specific Inclusion Criteria: 7. A diagnosis of IPF 8. IPF has been stable for ≥3 months at Screening PF-ILD-specific Inclusion Criteria: 9. Patients with physician diagnosed ILD who fulfill ≥1 of the following criteria for PF-ILD within 24 months of the Screening visit despite treatment with approved and/or unapproved medications used in clinical practice to treat ILD. 10. Fibrosing lung disease on HRCT performed within 3 years of the Screening Visit 11. For patients with underlying CTD: stable CTD as defined by no initiation of new therapy or withdrawal of therapy for CTD within 6 weeks before the Screening visit 12. FVC ≥45% predicted Part D only 13. Male or female patients of age ≥18 years 14. Clinical diagnosis of Graves' disease associated with active TED 15. Moderate-to-severe active TED 16. Less than 15 months from onset of TED in the study eye 17. No previous medical treatment for TED with the exception of local supportive measures, mycophenolate and oral or injectable steroids, immunomodulating therapies, and/or orbital irradiation/radiotherapy II. Participant Exclusion Criteria Parts A, B, C, and D 1. Any acute or chronic condition that would limit the participant's ability to participate in and complete this clinical study Part A and Part B only 2. Significant history or clinical manifestation of any significant endocrine, metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder 3. History of significant hypersensitivity; intolerance; or allergy to any drug compound, food, or other substance; or history of anaphylaxis or angioedema 4. Positive serum test for HIV or hepatitis infection 5. Currently receiving any antibiotics for upper or lower respiratory tract infections 6. Use of any prescription drug or vaccine within 21 days before Check-in with the exception of hormonal contraceptives and vaccines. 7. Any prescription biologic within 3 months or 5 half-lives (whichever is greater) before Check-in 8. Participation in any other investigational study drug trial in which an investigational study drug was administered within 30 days before randomization or an investigational biological study drug was administered within 3 months before Check-in Part C only 9. History of clinically relevant cardiovascular disease that could jeopardize a patient's health during the course of the study 10. Patients with concurrent active malignancy other than adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix IPF-specific Exclusion Criteria: 11. FVC \<45% predicted of normal or a forced expiratory volume during the first second of the forced breath (FEV1)/FVC ratio of \<0.7 12. Extent of emphysema in the lungs exceeds fibrosis 13. Currently receiving pirfenidone or nintedanib if on treatment for \<3 consecutive months or needed dose modification due to AEs in the last 3 months PF-ILD-specific Exclusion Criteria: 14. Diagnosis of IPF 15. Diagnosis of sarcoidosis 16. Significant pulmonary arterial hypertension 17. FVC \<45% predicted of normal or a FEV1/FVC ratio of \<0.7 18. Previous treatment with pirfenidone Part D only 19. Any previous use of anti-insulin-like growth factor 1 receptor monoclonal antibody (eg, teprotumumab) at any time 20. Patients with 2 mm proptosis decrease between Screening and Baseline, or a 1-point decrease on the CAS 7-point scale in any 2 weeks during the Screening period 21. Patients with decreased best corrected visual acuity due to optic neuropathy, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months before Screening